Drug Target Review
DECEMBER 20, 2024
” Weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways. Smith states, weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways.
Drug Target Review
APRIL 7, 2025
As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. 4 The definition has since evolved and expanded to include molecular signatures of pharmacodynamics and therapeutic response.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JULY 21, 2025
This absence of objective measures contributes to the variability in patient response to treatments, complicating efforts to produce standardised therapies. Moreover, regulatory pathways also change considerably based on the type of therapy – and guidance is sparse.
Drug Target Review
OCTOBER 30, 2024
In light of the natural composition of organs, a formal definition of an ‘organoid’ might be a mini organ in a dish that comprises all or most of the various cell types found in the organ being modelled. 22-26 Technically, these findings could apply to both restoration and enhancement of organ function.
PPD
MARCH 11, 2025
While there is no universally accepted definition for rare disease, it is estimated that more than 10,000 distinct rare conditions exist, and people living with these rare diseases represent as much as 10% of the global population.
The Pharma Data
JUNE 9, 2025
These results further validate the potential of Ascendis’ proprietary TransCon technology to deliver long-acting therapies that improve both efficacy and patient experience. Importantly, the combination therapy maintains a safety profile that aligns with what we’ve observed in monotherapy studies.” years in prior clinical studies.
Pharma Manufacturing
JUNE 17, 2025
“It is a higher quality, higher kind of technology so that entails higher capital investment, which is definitely not an easy step for any company,” Halkude said. When not covering the pharma manufacturing industry, he is an avid Buffalo Bills football fan, likes to kayak and plays guitar.
Expert insights. Personalized for you.
Let's personalize your content